| Old Articles: <Older 6881-6890 Newer> |
|---|
 |
IndustryWeek
November 17, 2010 |
IW 50: The Art of Making the da Vinci Intuitive Surgical approaches manufacturing with an innovation-first mindset.   |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
November 17, 2010
Bryan Hinmon |
Rising Star Buy: Medtronic Find out why this medical technology giant takes a place in our Un Portfolio. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
November 16, 2010
Brian Orelli |
Well, That Just Stinks Glaxo's Lovaza doesn't fix heart rhythm problems. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Anthera Seeks to Tap Heart Attack Market by Blocking Inflammation Anthera has some work to do to make sure its new drug wins big. |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
The Motley Fool
November 15, 2010
Dan Dzombak |
Are These Biotechs Creating Value? What economic value added momentum shows us about the folks running these biotech companies. |
The Motley Fool
November 12, 2010
Brian Orelli |
Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week. |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
| <Older 6881-6890 Newer> Return to current articles. |
